JP2020532537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532537A5 JP2020532537A5 JP2020512453A JP2020512453A JP2020532537A5 JP 2020532537 A5 JP2020532537 A5 JP 2020532537A5 JP 2020512453 A JP2020512453 A JP 2020512453A JP 2020512453 A JP2020512453 A JP 2020512453A JP 2020532537 A5 JP2020532537 A5 JP 2020532537A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cancer
- immune cells
- medicament according
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 40
- 210000002865 immune cell Anatomy 0.000 claims 33
- 239000000556 agonist Substances 0.000 claims 29
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims 26
- 108091008726 retinoic acid receptors α Proteins 0.000 claims 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 23
- 238000000034 method Methods 0.000 claims 17
- 102000003702 retinoic acid receptors Human genes 0.000 claims 16
- 108090000064 retinoic acid receptors Proteins 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 10
- 230000004069 differentiation Effects 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 230000001939 inductive effect Effects 0.000 claims 10
- 239000012190 activator Substances 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 238000002619 cancer immunotherapy Methods 0.000 claims 6
- 208000009527 Refractory anemia Diseases 0.000 claims 5
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 3
- 102000017578 LAG3 Human genes 0.000 claims 3
- 101150030213 Lag3 gene Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003467 diminishing effect Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000001024 immunotherapeutic effect Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 101000745891 Homo sapiens Cytochrome P450 26A1 Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 claims 2
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims 2
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical group C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000006017 1-propenyl group Chemical group 0.000 claims 1
- PNAWUIKCVQSLFG-UHFFFAOYSA-N 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=C(Cl)C(O)=C1C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1 PNAWUIKCVQSLFG-UHFFFAOYSA-N 0.000 claims 1
- -1 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001539 phagocyte Anatomy 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229950010130 tamibarotene Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552814P | 2017-08-31 | 2017-08-31 | |
| US62/552,814 | 2017-08-31 | ||
| PCT/US2018/048876 WO2019046591A1 (en) | 2017-08-31 | 2018-08-30 | SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532537A JP2020532537A (ja) | 2020-11-12 |
| JP2020532537A5 true JP2020532537A5 (https=) | 2021-10-07 |
Family
ID=65436409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512453A Pending JP2020532537A (ja) | 2017-08-31 | 2018-08-30 | がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10363272B2 (https=) |
| EP (1) | EP3675843A4 (https=) |
| JP (1) | JP2020532537A (https=) |
| KR (1) | KR20200044889A (https=) |
| CN (1) | CN111148514A (https=) |
| AU (1) | AU2018326617B2 (https=) |
| CA (1) | CA3073953A1 (https=) |
| IL (1) | IL272971A (https=) |
| MX (1) | MX2020002262A (https=) |
| NZ (1) | NZ761401A (https=) |
| SG (1) | SG11202001479RA (https=) |
| WO (1) | WO2019046591A1 (https=) |
| ZA (1) | ZA202001884B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316583A (zh) | 2005-09-30 | 2008-12-03 | 生命医药公司 | 用特异性rxr激动剂治疗癌症 |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| WO2013090616A1 (en) | 2011-12-13 | 2013-06-20 | Io Therapeutics, Inc. | Autoimmune disorder treatment using rxr agonists |
| CN116077626A (zh) | 2015-10-31 | 2023-05-09 | Io治疗公司 | 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱 |
| US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
| KR102605349B1 (ko) | 2016-03-10 | 2023-11-22 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
| US10363272B2 (en) | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| CN112390731B (zh) * | 2020-11-16 | 2022-11-25 | 成都大学 | 一种具有多靶点的维甲酸类衍生物及其制备方法与应用 |
| CA3242047A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
| AU2022408160A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist and taxanes in treating her2+ cancers |
| JP2025521810A (ja) * | 2022-06-27 | 2025-07-10 | アイオー セラピューティクス インコーポレイテッド | テトラヒドロナフタレノール類の合成およびその用途 |
| KR102874422B1 (ko) | 2022-11-04 | 2025-10-22 | 한국원자력연구원 | 무정전 전원을 갖는 환경방사선 감시시스템의 전원 시스템 및 그 방법 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1576007A (en) | 1976-02-11 | 1980-10-01 | Beecham Group Ltd | Hypolipidaemic compositions |
| US4326055A (en) | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
| US5234926A (en) | 1987-03-20 | 1993-08-10 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5324840A (en) | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
| EP0638071B1 (en) | 1992-12-28 | 1997-04-09 | Eisai Co., Ltd. | Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar) |
| CA2138000A1 (en) | 1994-01-03 | 1995-07-04 | John E. Starrett, Jr. | Retinoid-like compounds |
| US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US6942980B1 (en) | 1995-09-01 | 2005-09-13 | Allergan, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
| FR2739557B1 (fr) | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5723666A (en) | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| CA2263817A1 (en) | 1996-08-28 | 1998-03-05 | Centre National De La Recherche Scientifique | Therapeutic combinations of rar antagonists and rxr agonists and use thereof |
| US5739338A (en) | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
| US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| HK1047752A1 (zh) | 1999-06-11 | 2003-03-07 | Allergan, Inc. | 具有核激素受体调节活性的有机硅化合物 |
| WO2001007028A2 (en) | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
| TWI281911B (en) | 2000-04-04 | 2007-06-01 | Allergan Inc | Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents |
| SI1324970T1 (sl) | 2000-10-02 | 2009-02-28 | Hoffmann La Roche | Retinoidi za zdravljenje emfizema |
| EP1353217A1 (en) | 2002-03-29 | 2003-10-15 | JSR Corporation | Optical alignment method and liquid crystal display element |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| WO2005046726A2 (en) | 2003-11-12 | 2005-05-26 | Allergan, Inc. | Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist |
| US7476673B2 (en) | 2003-12-30 | 2009-01-13 | Allergan, Inc. | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors |
| WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| CN101316583A (zh) | 2005-09-30 | 2008-12-03 | 生命医药公司 | 用特异性rxr激动剂治疗癌症 |
| TR201819157T4 (tr) | 2006-05-16 | 2019-01-21 | Io Therapeutics Llc | Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti |
| WO2008121570A1 (en) | 2007-03-29 | 2008-10-09 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| CL2008003526A1 (es) * | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| PT2594590E (pt) * | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2011262758B8 (en) * | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| US9446105B2 (en) * | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US9790282B2 (en) * | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| WO2014163684A1 (en) | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| KR102442436B1 (ko) * | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| US9555031B2 (en) | 2014-04-11 | 2017-01-31 | The University Of North Carolina At Chapel Hill | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
| WO2016015095A1 (en) | 2014-07-31 | 2016-02-04 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| MX2017002875A (es) | 2014-09-08 | 2017-05-30 | Celgene Corp | Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1. |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| CN107427581A (zh) | 2014-12-25 | 2017-12-01 | 株式会社癌免疫研究所 | T细胞群的改变方法 |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3267969A1 (en) * | 2015-03-09 | 2018-01-17 | King's College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| MA53355A (fr) * | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| AU2016317915B2 (en) * | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| KR20180063320A (ko) | 2015-10-20 | 2018-06-11 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| EP3380086B1 (en) * | 2015-11-25 | 2021-10-13 | IO Therapeutics, Inc. | Cyp26-resistant rar-alpha selective agonists in the treatment of cancer |
| EP3383908A1 (en) * | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| WO2017201200A1 (en) | 2016-05-19 | 2017-11-23 | Orphagen Pharmaceuticals, Inc. | Therapeutic compositions containing rar-alpha antagonists |
| WO2017214575A1 (en) | 2016-06-10 | 2017-12-14 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
| US10363272B2 (en) | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
-
2018
- 2018-08-30 US US16/117,372 patent/US10363272B2/en active Active
- 2018-08-30 CA CA3073953A patent/CA3073953A1/en active Pending
- 2018-08-30 EP EP18852337.7A patent/EP3675843A4/en active Pending
- 2018-08-30 CN CN201880056488.6A patent/CN111148514A/zh active Pending
- 2018-08-30 JP JP2020512453A patent/JP2020532537A/ja active Pending
- 2018-08-30 KR KR1020207008540A patent/KR20200044889A/ko not_active Ceased
- 2018-08-30 AU AU2018326617A patent/AU2018326617B2/en active Active
- 2018-08-30 NZ NZ761401A patent/NZ761401A/en unknown
- 2018-08-30 MX MX2020002262A patent/MX2020002262A/es unknown
- 2018-08-30 WO PCT/US2018/048876 patent/WO2019046591A1/en not_active Ceased
- 2018-08-30 SG SG11202001479RA patent/SG11202001479RA/en unknown
-
2019
- 2019-06-26 US US16/452,800 patent/US10532073B2/en active Active
- 2019-07-23 US US16/519,544 patent/US10532074B2/en active Active
- 2019-12-12 US US16/711,627 patent/US10874694B2/en active Active
-
2020
- 2020-02-27 IL IL272971A patent/IL272971A/en unknown
- 2020-03-24 ZA ZA2020/01884A patent/ZA202001884B/en unknown
- 2020-12-16 US US17/123,577 patent/US11786555B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532537A5 (https=) | ||
| US20230310595A1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| JP2021183650A (ja) | 治療用組成物、組合せ物および使用の方法 | |
| KR102705821B1 (ko) | 항암제 | |
| JPWO2019124500A1 (ja) | Ｔｌｒ７アゴニストを含む併用薬 | |
| JP2017532372A5 (https=) | ||
| RU2017112379A (ru) | Сочетанные способы лечения с использованием ингибиторов alk | |
| JP2018519327A5 (https=) | ||
| Lonez et al. | Celyad's novel CAR T-cell therapy for solid malignancies | |
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| JP7154634B2 (ja) | 腫瘍免疫賦活剤 | |
| Yang et al. | Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy | |
| JP2022512539A5 (https=) | ||
| JP7636322B2 (ja) | 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用 | |
| CN110891944B (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| Kothari et al. | Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects | |
| HK40075828A (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |